Physician profile
Debra Phillips
NPI 1316456726
$1,245.81
in general payments reported to CMS, 2019-2025
21 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $227 · 2023: $254 · 2024: $121 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $242.32 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $231.65 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $117.72 | 2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $86.53 | 2023-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $78.66 | 2021-2024 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $62.33 | 2022-2023 | |
| Amarin Pharma, INC. | $60.91 | 2021 | |
| Pfizer INC. | $54.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.39 | 2023 | Gattex |
| Lilly USA, LLC | $42.75 | 2025 | Kisunla, Zepbound, Mounjaro |
| Genentech USA, INC. | $39.56 | 2021-2022 | |
| Mylan Specialty L.P. | $31.47 | 2022 | |
| Abbott Laboratories | $23.00 | 2025 | Freestyle Libre 3 |
| Csl Behring | $20.99 | 2023 | Haegarda |
| Otsuka America Pharmaceutical, INC. | $18.52 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2023 | Cycloset |
| Ardelyx, INC. | $17.48 | 2023 | Ibsrela |
| Currax Pharmaceuticals LLC | $14.88 | 2023 | Nexlizet, Contrave, Nexletol |
| Amneal Pharmaceuticals LLC | $14.23 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2022 | |
| Glaxosmithkline, LLC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.